Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 25, 2007Diabetes CareOpen Access

Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

Daniel J. Drucker
Daniel J. DruckerUniversity of Toronto

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Daniel J. Drucker (2007) studied this question.

synapsesocial.com/papers/69e7aa8ffc331e92bc6d2a95https://doi.org/10.2337/dc07-0228
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes2005 · 362 citations
  2. 2Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.1998 · 320 citations
  3. 3Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders2005 · 336 citations
  4. 4Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum1993 · 1,169 citations
  5. 5CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation2006 · 99 citations